Updates from New Orleans: Best of Ophthalmology Research on New and Emerging GA Therapies
This activity is supported by an educational grant from Iveric Bio.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Iveric Bio.
Activity Description
Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapies and the anticipated approval of another, clinicians must be prepared to incorporate these treatment approaches into practice. Moreover, there have been major advances in the diagnosis and monitoring of GA that have substantially impacted its management. In this educational activity, experts in the field of vascular retina diseases review the most compelling data in GA that were presented at the most recent Annual Meeting of the American Research in Vision and Ophthalmology (ARVO). They also discuss their clinical relevance, while providing practical guidance on the optimal incorporation of these novel agents that target the complement cascade into clinical practice.
Target Audience
The intended audience for this activity is ophthalmologists, optometrists, retina specialists, and other healthcare professionals involved in the management of patients with GA secondary to AMD.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize how new and emerging therapies for GA secondary to AMD can fit into the treatment paradigm to optimize its management.
- Detail how the use of imaging can be used to effectively detect as well as monitor GA treatment and the progression of disease.
- Examine new clinical efficacy and safety data on therapies that have reduced vision loss in patients with GA.
Activity Chair
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV
Faculty
Carl J. Danzig, MD, FASRS
Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, FL
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, FL
Lejla Vajzovic, MD, FASRS
Director, Duke Surgical Vitreoretinal Fellowship Program
Director, Duke Center for Artificial and Regenerative Vision
Co-Director, Duke Pediatric Retina and Optic Nerve Center
Director, Duke Eye Center Continuing Medical Education
Director, Duke fAVS and AVS Courses
Associate Professor of Ophthalmology
Adult and Pediatric Vitreoretinal Surgery and Diseases
Duke University Eye Center
Durham, NC
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Mark T. Dunbar, OD, FAAO
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity will also award credit for optometry (COPE) if the requirements necessary for credit are met.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education designates this enduring activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.
COPE Course ID: 84763-TD
COPE Activity ID: 126179
This enduring material is approved for 1 year from the date of original release, May 24, 2023, to May 23, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or COPE CE Certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Carl J. Danzig, MD, FASRS
Consultant: AbbVie, Genentech, Iveric Bio, Regenxbio, Roche
Speaker Contracted by Ineligible Company: Genentech
Independent Research Contractor: Genentech, Gyroscope, Iveric Bio, Novartis, Regenxbio, Roche
Arshad M. Khanani, MD, MA
Consultant: 4DMT, Adverum, Apellis, Aviceda, Broadwing Bio, Chengdu Kanghong, Gemini, Genentech, Graybug, Gyroscope, Iveric Bio, Novartis, Oculis, Retrotope, Regenxbio, RevOpsis, Roche
Speaker Contracted by Ineligible Company: Genentech, Novartis
Independent Research Contractor: 4DMT, Adverum, Apellis, Chengdu Kanghong, Gemini, Genentech, Graybug, Gyroscope, Iveric Bio, NGM Bio, Novartis, Oculis, Regenxbio, Roche
Individual Stocks and Stock Options: Aviceda, Retrotope
Lejla Vajzovic, MD, FASRS
Consultant: Apellis, Gyroscope, Heidelberg Engineering, Iveric Bio, Novartis, Regenxbio, Roche/Genentech
Independent Research Contractor: Gyroscope, Heidelberg Engineering
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Mark T. Dunbar, OD, FAAO
Consultant: Iveric Bio, Zeiss
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Expert Panel is available upon request. Requests should include the activity title and emailed to CME@VindicoCME.com. Requests will be honored within 3 to 5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com